Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.07.2023 | Case report

Gemcitabine/trametinib

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Luo X, et al. A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report. Frontiers in Immunology 13: 951422, et al. Oct 2022. Available from: URL: http://doi.org/10.3389/fimmu.2022.951422 Luo X, et al. A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report. Frontiers in Immunology 13: 951422, et al. Oct 2022. Available from: URL: http://​doi.​org/​10.​3389/​fimmu.​2022.​951422
Metadaten
Titel
Gemcitabine/trametinib
Lack of efficacy: case report
Publikationsdatum
01.07.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-42762-9

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Minocycline

Case report

Imatinib

Case report

Prednisone

Case report

Multiple drugs